Skip to Content
Søg Menu

Exceptional Response of Lorlatinib and Cabozantinib Combination in ROS1-Rearranged NSCLC

In this MEDtalk, Assistant Professor Tejas Patil presents a case with one of his patients having an exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance.
Tejas Patil

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

CheckMate 227: 6-års data om behandling af lokalt avanceret NSCLC med Opdivo og Yervoy 

/ BestPractice Nordic
WCLC23NSCLCLungecancer

Adjuverende behandling med 3. generations EGFR-TKI kan øge progressionsfri overlevelse 

/ BestPractice Nordic
WCLC23NSCLCLungecancer

WCLC 2023 – NSCLC: Nye data på perioperativ behandling med immunterapi  

/ BestPractice Nordic
WCLC23NSCLCLungecancerImmunterapi
Timothy F. Burns

Osimertinib for the Treatment of EGFR-Mutant NSCLC in the Adjuvant Setting

/ Timothy F. Burns
NSCLC Play the Video 10:15
Birgitte Bjørnhart

Real-World Studies Highlight NSCLC Data Gaps and Survival Differences from Randomized Controlled Trials

/ Birgitte Bjørnhart
DSKO23NSCLCLungecancer Play the Video 5:04
Astrid Telhaug Karlsson

Survival Rates for Patients with NSCLC with Brain Metastases following Whole Brain Radiotherapy

/ Astrid Telhaug Karlsson
ELCC23NSCLCLungecancer Play the Video 3:22
Niels Reinmuth

Current Aspects in Early-Stage NSCLC – Perspectives from ELCC23

/ Niels Reinmuth
ELCC23NSCLCLungecancer Play the Video 3:54
Siow Ming Lee

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Siow Ming Lee
ESMO22NSCLCLungecancer Play the Video 5:14

Bedre overlevelse for patienter med metastatisk ikke-småcellet lungecancer og hjernemetastaser

/ BestPractice Nordic
NSCLCHjernemetastaserLungecancerWCLC21
Back to top